AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $4.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $3K to $94K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$4.1M netNet selling
- CongressSTOCK Act, last 180 days
- -$3K to -$94K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 9 added, 4 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 2 awardsAwards on record
Key stats
Fundamentals Sep 27- Open
- $408.25
- 52-wk high
- $447.03
- High
- $415.20
- 52-wk low
- $263.36
- Low
- $404.19
- Prev close
- $406.04
- Mkt cap
- $224.15B
- P/E
- 25.8x
- Volume
- 2.21M
- Fwd P/E
- 16.7x
- Beta
- 0.43
- Div yield
- 2.41%
- P/S
- 5.9x
- P/B
- 18.8x
- Profit margin
- +23.0%
- Op margin
- +35.5%
- ROE
- +91.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about AMGN filings
Are insiders buying or selling Amgen Inc (AMGN) stock?
Net selling: insiders sold $4.1M and bought $0 of AMGN stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. The largest was Miller, Derek (SVP, Human Resources), who sold $1.6M. The latest filing was on Aug 13, 2026.
Which members of Congress have traded AMGN recently?
Rep. David J. Taylor (R) sold $1K to $15K on Aug 26, 2026, disclosed 10 days later. Rep. David J. Taylor (R) sold $1K to $15K on Aug 26, 2026, disclosed 10 days later. Sen. Sheldon Whitehouse (D) sold $1K to $15K on Aug 12, 2026, disclosed 21 days later. Rep. David J. Taylor (R) bought $1K to $15K on Jun 5, 2026, disclosed 7 days later. In total, 3 members disclosed 5 AMGN trades with trade dates in the last 180 days, filed a median 10 days after trading.
How current is this AMGN smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- DS
D.E. Shaw
$404.6M
added
- TS
Two Sigma
$383.5M
added
- CI
Citadel
$189.8M
added
What insiders are doing
What Congress is doing
How top traders are positioned
No tracked top-trader positions in AMGN right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 12.3% above what analysts expected.
Earnings per share
$5.60 expected
Revenue
No comparable estimate
FY2026 guidance
$38.20B to $39.40B
No comparable estimate
Reports Nov 3, 2026, in 37 days
Estimates as of Sep 27, 2026
EPS expected
$5.48 to $6.16
Revenue expected
24 analysts
Last 30 days
Analysts raising estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $9.56B | $9.90B | $8.62B | $10.05B |
| Cost of what it sold | $3.08B | $1.79B | $2.74B | $2.81B |
| Gross profit | $6.47B | $8.11B | $5.87B | $7.24B |
| What it spent | ||||
| Research and development | $1.90B | $2.15B | $1.72B | $1.87B |
| Sales and admin | $1.72B | $1.95B | $1.60B | $1.75B |
| Other operating costs | $329.0M | $61.0M | -$113.0M | $116.0M |
| Total operating expenses | $3.95B | $4.16B | $3.21B | $3.73B |
| What was left | ||||
| Operating profit | $2.53B | $3.94B | $2.67B | $3.51B |
| Interest on debt | $685.0M | $653.0M | $657.0M | $673.0M |
| Profit before tax | $3.92B | $1.51B | $2.08B | $2.77B |
| Tax | $705.0M | $181.0M | $265.0M | $393.0M |
| Net profit | $3.22B | $1.33B | $1.82B | $2.38B |
| EBITDA | $5.91B | $3.30B | $3.86B | $3.44B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Sarepta Therapeutics (SRPT) Falls As Patent Settlement Tests The Undervalued Narrative
NeutralSep 26How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story
BullishSep 26Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal
NeutralSep 25Merck, Daiichi withdraw ifinatamab FDA application
Leans bullishSep 25Amgen stock last at USD 410.86, up 1.19 percent in New York trading
Leans bullishSep 25Mesirow buys Amgen’s Deerfield campus in $151 million sale-leaseback
NeutralSep 25Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close
NeutralSep 25Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading
NeutralSep 25
Macro
32 macro signals shaping AMGN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results